BD (Becton, Dickinson and Company) has announced a development and global distribution agreement with Check-Points for BD MAX assays that detect carbapenem-resistant organisms (CRO).
As part of the agreement, BD will distribute the Check-Direct CPE Screen for the BD MAX assay (CE IVD) outside of the US, with Check-Points maintaining exclusivity in the Netherlands. Check-Points and BD plan to develop and commercialise a next-generation CRO assay for launch outside the US in 2017.